People with comorbidity(ies) are people:
- patients with cancers and malignant hematological diseases undergoing chemotherapy treatment
- with severe chronic kidney disease, including dialysis patients
- solid organ transplant recipients
- transplanted by allograft of hematopoietic stem cells
- suffering from chronic poly-pathologies and presenting at least two organ deficiencies
- suffering from certain rare diseases and particularly at risk in the event of infection (specific list drawn up by the COS and the rare disease health sectors)
- with trisomy 21
- with cystic fibrosis
Pathologies at high risk of serious forms are:
- Angiopathie de moyamoya
- APECED : ou polyendocrinopathie auto-immune de type 1
- CADASIL and related familial vascular leukoencephalopathies
- Cyanotic syndromic congenital heart disease with unstable heart failure
- Hereditary brain cavernomas
- Intracellular trafficking deficits in children (NBAS: neuroblastoma amplified sequence)
- Hereditary immune deficiencies:
- Patients with AIRE, NFBK2, and interferon deficiencies
- Patients with defective production and/or response to interferon alpha (which includes
defaults IFNAR, UNC, TLR3) - SASH3: an ultra-exceptional form that sometimes associates neutropenia with a lymphocyte deficit
- Hereditary Cervical and Cerebral Artery Dissections
- Severe hereditary epidermolysis bullosa with cardiac or renal involvement (syndromic forms) or EBDR type (multi-systemic forms)
- Pulmonary fibrosis associated with connectivitis (systemic sclerosis, rheumatoid arthritis,
other connections) - Idiopathic pulmonary fibrosis
- Pulmonary fibrosis secondary to pneumoconioses (occupational lung diseases).
- Ventilation-dependent syndromic congenital pulmonary fibrosis
- Diaphragmatic dome hernia (only for patients on oxygen or with anti-PAH treatment)
- Pulmonary Arterial Hypertension (PAH)
- Pulmonary hypertension associated with chronic respiratory diseases (HTP-MRC)
- Chronic Pulmonary Thrombo-Embolic Hypertension (HTP-TEC)
- Incontinence of pigment
- Diseases at risk of acute decompensation in case of fever, only for very unstable cases: intoxication diseases, energy diseases
- severe neurological disability
- Rare systemic autoimmune diseases:
- Patients on prolonged high-dose corticosteroid therapy
- Patients receiving or who will receive immunosuppressants and RITUXIMAB
- Bullous autoimmune diseases (Pemphigus and Pemphigoides) requiring prolonged corticosteroid therapy and/or Rituximab
- Neurodegenerative diseases with severe swallowing disorders leading to choking
- Rare digestive diseases: Immunocompromised patients or on immunosuppressants (in the broad sense including biotherapies)
- Rare liver diseases under immunosuppressants, in particular autoimmune hepatitis (with or without transplant)
- Cerebral arteriovenous malformations
- cystic fibrosis
- Neuropathies and myopathies associated with respiratory failure with FVC < 70% or heart failure
- Autoimmune pancreatitis (under immunosuppressants or not) type 1 (IgG4 disease)
- Autoimmune pancreatitis (under immunosuppressants or not) type 2
- Chronic pancreatitis complicated by diabetes (type 3, pancreaticoprive) regardless of age (all rare causes of chronic pancreatitis combined: genetics (PRSS1, SPINK1, CTRC, CFTR, CPA1, CaSR, Cel-Cyb …….), tryglyceridemia on FCS or MCS, idiopathic, pancreatic malformations…)
- Constitutional bone pathologies with respiratory failure, with restrictive syndromes / thoracic deformity or renal failure or multi-organ involvement or immune deficiency
- Patients with multiple sclerosis or chronic inflammatory rheumatism AND under anti-CD20 treatment
- Patients with vasculitis (ANCA vasculitis, rheumatoid purpura nephropathy etc etc) glomerulonephritis with mesangial IgA deposits, glomerulonephritis with C3 deposits and receiving immunosuppressive treatment exposing them to an increased risk of severe form of Covid-19
- Patients with systemic lupus undergoing immunosuppressive treatment exposing them to an increased risk of a severe form in the event of Covid-19. (Preferably vaccinate outside of any outbreak)
- Patients with active NIS (SNLGM or HSF) or active GEM and/or undergoing immunosuppressive treatment exposing them to an increased risk of severe form in the event of Covid-19 (prolonged corticosteroid therapy, anti CD20, mycophenolate mofetil, azathioprine, cyclophosphamide, anticalcineurins (Ciclopsorine, Prograf))
- Persons with an immune complication in the form of antibodies once morest their usually used therapeutic principle (e.g. haemophilia with anti-factor VIII or anti-factor IX antibodies)
- People with constitutional bleeding disorders who use a drug in a clinical trial
- People suffering from constitutional haemorrhagic diseases who have an identified comorbidity (hepatitis C, hypertension, diabetes, etc.)
- Amyotrophic Lateral Sclerosis (ALS)
- Brugada syndrome
- Cerebral vein thrombosis
Severely immunocompromised people are people:
- who have received an organ or hematopoietic stem cell transplant
- under lymphopenic chemotherapy
- treated with strong immunosuppressive drugs, such as antimetabolites (cellcept, myfortic, mycophenolate mofetil, imurel, azathioprine) and AntiCD20 (rituximab: Mabthera, Rixathon, Truxima)
- chronic dialysis following consulting their attending physician who will decide on the need for appropriate examinations
- on a case-by-case basis, people on immunosuppressants who do not fall into the above categories or who have a primary immunodeficiency
Consult the list of rare pathologies justifying vaccination as a very high priority once morest Covid-19
For more information on Covid-19: consult our frequently asked questions
